› 2q7l

X-ray diffraction
1.92Å resolution

The Androgen Receptor Prostate Cancer Mutant H874Y Ligand Binding Domain Bound with Testosterone and a TIF2 box3 Coactivator Peptide 740-753

Released:
DOI: 10.2210/pdb2q7l/pdb
PDB entry 2q7l coloured by chain, front view.
PDB entry 2q7l coloured by chain, side view.
PDB entry 2q7l coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
Askew EB, Gampe RT, Stanley TB, Faggart JL, Wilson EM
J Biol Chem 282 25801-16 (2007)
PMID: 17591767

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-145245 (preferred)
Entry contents:
2 distinct polypeptide molecules
Macromolecules (2 distinct):
Androgen receptor Chain: A
Molecule details ›
Chain: A
Length: 257 amino acids
Theoretical weight: 30.03 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P10275 (Residues: 664-920; Coverage: 28%)
Gene names: AR, DHTR, NR3C4
Sequence domains: Ligand-binding domain of nuclear hormone receptor
Structure domains: Retinoid X Receptor
Nuclear receptor coactivator 2 Chain: B
Molecule details ›
Chain: B
Length: 14 amino acids
Theoretical weight: 1.71 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: Q15596 (Residues: 740-753; Coverage: 1%)
Gene names: BHLHE75, NCOA2, SRC2, TIF2

Ligands and Environments

2 bound ligands:
Ligand TES 1 x TES
Ligand GOL 1 x GOL
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: APS BEAMLINE 17-BM
Spacegroup: P212121
Unit cell:
a: 54.428Å b: 66.79Å c: 69.94Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.184 0.182 0.221
Expression system: Escherichia coli

Quick links

Citations

32 review citations

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.
Harris et al. (2009)
31 more

5 mentions without citation

Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
Askew et al. (2007)
4 more